Kyle Chenet
Chief Executive Officer at 410 Medical, Inc.
Profile
Kyle Chenet is currently the Chief Executive Officer & Director at 410 Medical, Inc. He previously held positions as the Chief Executive Officer at Lq3 Pharmaceuticals, Inc., Director-Business Development at Biolex Therapeutics, Inc., Director-Worldwide Business Development at GSK Plc, Manager at Abbott Laboratories, Vice President-Corporate Development at Liquidia Technologies, Inc., and Vice President-Corporate Development at Envisia Therapeutics, Inc. He holds an MBA from Stanford University and an undergraduate degree from the University of Michigan.
Kyle Chenet active positions
| Companies | Position | Start |
|---|---|---|
410 Medical, Inc.
 410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Chief Executive Officer | - |
Former positions of Kyle Chenet
| Companies | Position | End |
|---|---|---|
Biolex Therapeutics, Inc.
 Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC. | Corporate Officer/Principal | - |
Lq3 Pharmaceuticals, Inc.
 Lq3 Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Lq3 Pharmaceuticals, Inc. develops innovative oral health therapies. It utilizes PRINT (Particle Replication In Non-Wetting Templates) technology to research and develop solutions for an assortment of oral health issues. The firm's technology offers many advantages, such as tunable release kinetics, targeting, improved drug loading, delivery of biologics and combination products. The company was founded in 2014 and is headquartered in Garland, TX. | Chief Executive Officer | - |
| GSK PLC | Corporate Officer/Principal | - |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Corporate Officer/Principal | - |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Training of Kyle Chenet
| University of Michigan | Undergraduate Degree |
| Stanford University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| GSK PLC | Health Technology |
| Private companies | 5 |
|---|---|
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Biolex Therapeutics, Inc.
Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC. | Distribution Services |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Health Technology |
Lq3 Pharmaceuticals, Inc.
Lq3 Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Lq3 Pharmaceuticals, Inc. develops innovative oral health therapies. It utilizes PRINT (Particle Replication In Non-Wetting Templates) technology to research and develop solutions for an assortment of oral health issues. The firm's technology offers many advantages, such as tunable release kinetics, targeting, improved drug loading, delivery of biologics and combination products. The company was founded in 2014 and is headquartered in Garland, TX. | Health Services |
410 Medical, Inc.
410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Kyle Chenet
